Vital Therapies, Inc. Expands Board of Directors
20 Septembre 2013 - 12:00PM
Marketwired
Vital Therapies®, Inc. (VTI), a biopharmaceutical company
developing a cell-based therapy targeting the treatment of acute
liver failure, today announced election of Jean-Jacques Bienaimé to
the company's Board of Directors.
Jean-Jacques Bienaimé is the Chief Executive Officer and a
member of the Board of Directors of BioMarin® Pharmaceutical Inc.,
(NASDAQ: BMRN), a market-leader in the development and
commercialization of innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio
comprises four approved orphan drug products and multiple clinical
and pre-clinical product candidates. Approved products include
Naglazyme® (galsulfase) for mucopolysaccharidosis VI, Kuvan®
(sapropterin dihydrochloride) for phenylketonuria, Aldurazyme®
(laronidase) for mucopolysaccharidosis I, and Firdapse™
(amifampridine phosphate) for Lambert-Eaton myasthenic
syndrome.
Under Mr. Bienaimé's leadership BioMarin's market capitalization
has grown from its May 2005 value of $450 million to its current
value of $11 billion. The company generated $500.7 million in
revenue in 2012, a 13.4% increase over the prior 12 months.
Mr. Bienaimé is a member of the board of directors of InterMune,
Inc. (NASDAQ: ITMN), a member of the board of directors of Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA), and a member of the board of
directors for Biotechnology Industry Organization. He received an
M.B.A from the Wharton School at the University of Pennsylvania and
a degree in economics from the Ecole Superieure de Commerce de
Paris.
Muneer Satter, VTI's Co-Chairman and Lead Director said, "We are
delighted to have Mr. Bienaimé's invaluable guidance on our Board
of Directors. BioMarin is a true innovator in the development and
marketing of orphan biologic therapies. We welcome JJ's expert
advice as we enter our phase 3 trials and soon begin preparations
for potential commercialization."
About Vital Therapies Inc
Vital Therapies, Inc. is a private biopharmaceutical company
developing a cell-based therapy targeting the treatment of acute
liver failure. The company's lead product-candidate, ELAD, is an
extra-corporeal bio-artificial liver currently in phase 3 clinical
trials. VTI is based in San Diego, California.
About ELAD
ELAD is a Phase 3 investigational extracorporeal bio-artificial
liver therapy designed to supplement hepatic function in order to
improve survival rates among patients with acute liver failure.
ELAD consists of a re-usable bedside unit attached to four
disposable cartridges, which collectively contain thousands of
hollow fibers and approximately one pound of immortal human C3A
cells from our proprietary cell bank. The patient's plasma flows
inside of the hollow fibers to allow two-way transfer of
metabolites. The system has been shown to process toxins, and
synthesize proteins and metabolites in ways that mimic components
of normal human liver function. The ELAD cell cartridges are
produced at VTI's GMP-compliant facility in San Diego, California.
Moreover, the therapy has received Orphan Designation in both the
United States and Europe for the treatment of acute liver
failure.
Vital Therapies® and ELAD® are trademarks of Vital Therapies,
Inc.
BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered
trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme
LLC.
This press release may contain forward-looking statements,
including but not limited to statements regarding current and
future clinical studies in our Phase 3 program and ELAD's potential
market launch. These statements relate to future events and are
subject to risks, uncertainties and assumptions about Vital
Therapies, Inc. These statements are only predictions based on our
current expectations and projections about future events. You
should not place undue reliance on these statements. Actual events
or results may differ materially. Many factors may cause our actual
results to differ materially from any forward-looking statement. We
do not undertake to update any forward-looking statements.
CONTACT: Terry Winters Co-Chairman & Chief Executive Officer
or Duane Nash Chief Business Officer Vital Therapies, Inc.
858-673-6840
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024